Dergiler / European Journal of Rheumatology / 2015 / Cilt: 2 - Sayı: 2

Sarcopenia in women with rheumatoid arthritis

Sayfa
57–61
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: It was found that SMI was decreased and sarcopenia risk was elevated in patients with RA and the risk was higher in non-obese patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To assess sarcopenia status in women with rheumatoid arthritis (RA).
📊
Temel Bulgular & Veri:Material and Methods: Thirty female patients with RA and 30 female controls without RA were enrolled in this study.
💡
Sonuç & Katkı:Conclusion: It was found that SMI was decreased and sarcopenia risk was elevated in patients with RA and the risk was higher in non-obese patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: To assess sarcopenia status in women with rheumatoid arthritis (RA). Material and Methods: Thirty female patients with RA and 30 female controls without RA were enrolled in this study. Sarcopenia status in patients with RA was evaluated by assessing body composition using dual X-ray absorptiometry (DXA). C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR) were measured, and body mass index (BMI) and Disease Activity Score (DAS28) were calculated. Because sarcopenia differs between men and women, the study groups comprised only females. Results: It was found that skeletal muscle index (SMI) was lower in patients with RA (5.83±0.807) than in controls (7.30±1.640). Sarcope-nia (in females with an SMI of ≤5.75 kg/m2) was more common in the RA group and the difference was statistically significant (p=0.004). Sarcopenia was more common in patients with RA who were normal or overweight than in those who were obese according to their BMI. There was no relationship between sarcopenia and DAS28 in the RA group (p=0.530), whereas CRP levels were significantly higher in patients with sarcopenia (p=0.230). No relationship was found between drug use and sarcopenia in the RA group. Conclusion: It was found that SMI was decreased and sarcopenia risk was elevated in patients with RA and the risk was higher in non-obese patients.

🔖

Bu Makaleye Atıf Yap

HAYTA, E., GÜLER, E., ERSELCAN, T., CEYHAN, S. D., HİZMETLİ, S., KAPTANOĞLU, E. (2022). Sarcopenia in women with rheumatoid arthritis. European Journal of Rheumatology, Cilt: 2 - Sayı: 2, 57–61. https://ajindex.com/articles/511794

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Firestein GS. Clinical features of rheumatoid arthitis. In: Harris ED, Budd CR Firestein GS ed-itors. Kelley’s Textbook of Rheumatology. Phila-delphia; 2005. p. 996-42
  2. Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Ander-sen RE, Towns M. Abnormal body composition phenotypes in older rheumatoid arthritis pa-tients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008; 59: 807-15. [CrossRef] 3. Gallagher D, Ruts E, Visser M, Heshka S, Baumgart-ner RN, Wang J. Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocri-nol Metab 2000; 279: 366-75
  3. Rolland Y, Czerwinski S, Abellan Van Kan G, Mor-ley JE, Cesari M, Onder G. Sarcopenia: its assess-ment, etiology, pathogenesis, consequences and future perspectives. The Journal of Nutrition, Health & Aging, 2008; 7: 433-50. [CrossRef] 5. Rocha O M, Batista A P, Maestá N, Burini RC, Lau-rindo IMM. Sarcopenia in rheumatoid cachexia: definition, mechanisms, clinical consequences and potential therapies. Bras J Rheumatol 2009; 49: 288-01
  4. Greenlund LJ, Nair KS. Sarcopenia-consequenc-es mechanisms and potential therapies. Aging 2003; 124: 287-99. [CrossRef] 7. Guler H. Approach to the geriatric patients with musculoskeletal system diseases. Turkiye Klinikleri J Int Med Sci 2005; 1: 16-21
  5. Roubenoff R, Rall R. C. Rheumatoid Cachexia: metabolic abnormalities, mechanisms and in-terventions. Rheumatology 2004; 43: 1219-23. [CrossRef] 9. Roubenoff R, Roubenoff RA, Cannon JG, Ke-hayias JJ, Zhuang H, Dawson-Hughes B et al. Rheumatoid Cachexia: Cytokine-driven Hy-permetabolism Accompanying Reduced Body Cell Mass in Chronic Inflammation. J Clin Invest 1994; 93: 2379-86. [CrossRef] 10. Arnett FC, Edwothy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. [CrossRef] 11. Abellan Van Kan G. Epidemiology and Conse-quences of Sarcopenia. J Nutr Health Aging 2009; 13: 708-12. [CrossRef] 12. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints as-sociated with elevated physical disability risk in older men and women. Am J Epidemiol 2004; 159: 413-21. [CrossRef] 13. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percent-age body fat ranges: an approach for develop-ing guidelines based on body mass index. Am J Clin Nutr 2000; 72: 694-01
  6. Garrouste-Orgeas M, Troché G, Azoulay E,